CTX112 Trademark

Trademark Overview


On Wednesday, April 20, 2022, a trademark application was filed for CTX112 with the United States Patent and Trademark Office. The USPTO has given the CTX112 trademark a serial number of 97371562. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Monday, February 3, 2025. This trademark is owned by CRISPR Therapeutics AG. The CTX112 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases
ctx112

General Information


Serial Number97371562
Word MarkCTX112
Filing DateWednesday, April 20, 2022
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateMonday, February 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 23, 2024

Trademark Statements


Goods and ServicesCells for medical or clinical use in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy
Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 26, 2022
Primary Code005
First Use Anywhere DateFriday, March 24, 2023
First Use In Commerce DateFriday, March 24, 2023

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 26, 2022
Primary Code042
First Use Anywhere DateFriday, March 24, 2023
First Use In Commerce DateFriday, March 24, 2023

Trademark Owner History


Party NameCRISPR Therapeutics AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressZUG V8 6300
CH

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressZUG V8 6300
CH

Trademark Events


Event DateEvent Description
Saturday, April 23, 2022NEW APPLICATION ENTERED
Tuesday, April 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 7, 2023ASSIGNED TO EXAMINER
Tuesday, February 14, 2023NON-FINAL ACTION WRITTEN
Tuesday, February 14, 2023NON-FINAL ACTION E-MAILED
Tuesday, February 14, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 11, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, May 11, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, July 3, 2023ASSIGNED TO EXAMINER
Thursday, August 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 11, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 2, 2023FINAL REFUSAL WRITTEN
Monday, October 2, 2023FINAL REFUSAL E-MAILED
Monday, October 2, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, December 18, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, December 18, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, February 16, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, February 16, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 15, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 18, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 28, 2024USE AMENDMENT FILED
Monday, October 28, 2024TEAS STATEMENT OF USE RECEIVED
Saturday, January 11, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 13, 2025STATEMENT OF USE PROCESSING COMPLETE
Monday, February 3, 2025SU - NON-FINAL ACTION - WRITTEN
Monday, February 3, 2025NON-FINAL ACTION E-MAILED
Monday, February 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED